Daiichi's a-fib drug aces PhIII, faces crowded market

Daiichi Sankyo's atrial fibrillation-treating edoxaban posted promising results in Phase III, matching the stroke-prevention prowess of warfarin with a better safety profile, but the drug may struggle to carve out market share in a cluttered space. Daiichi plans to file for approval early next year, and, with the FDA's blessing, edoxaban would compete with Johnson & Johnson ($JNJ) and Bayer's Xarelto, Bristol-Myers Squibb ($BMY) and Pfizer's ($PFE) Eliquis, and Boehringer Ingelheim's Pradaxa, not to mention the still-popular and ever-cheap warfarin. Article

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.